-
Views
-
Cite
Cite
Endocrinology & Metabolism News, The Journal of Clinical Endocrinology & Metabolism, Volume 94, Issue 12, 1 December 2009, Pages 17a–20a, https://doi.org/10.1210/jcem.94.12.9991
- Share Icon Share
Extract
Endocrine Discovery
The incidence of lung cancer was not significantly different among women assigned to combined postmenopausal hormone replacement compared with placebo, but more deaths occurred from non-small-cell lung cancer with combined therapy (62 vs. 31 deaths; hazard ratio, 1.87; 95% CI, 1.22–2.88, P = 0.004) after a mean of 5.6 years of treatment and 2.4 years of additional follow-up in a post hoc analysis of lung cancers diagnosed in women who participated in the Women’s Health Initiative (WHI). (Lancet [October 10, 2009] 374(9697):1243)
Use of darbepoetin alfa in patients with diabetes and chronic kidney disease not on dialysis did not reduce risk of death, cardiovascular disease, or end-stage renal failure, and it was associated with a higher rate of fatal and nonfatal stroke (hazard ratio, 1.92; 95% CI, 1.38–2.68; P < 0.001) in a prospective randomized placebo-controlled study of darbepoetin alfa in 4038 patients, over a median follow-up period of 29 months. (N Engl J Med [published online ahead of print October 30, 2009])